Baillie Gifford acquired 939 Thousand Cardlytics shares worth $7.9 Million. That's 0.01% of their equity portfolio (221st largest holding). The investor owns 1.81% of the outstanding Cardlytics stock. The first Cardlytics trade was made in Q1 2021. Since then Baillie Gifford bought shares seven more times and sold shares on five occasions. The investor's estimated purchase price is $73.2 Million, resulting in a loss of 89%.